Guest: Aaron M. Potretzke, M.D. (@potretzke)

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

Microscopic hematuria, and less commonly gross hematuria, are conditions commonly seen by the primary care provider. Malignancy is the most ominous cause of hematuria. Fortunately, other causes are much more likely. Since this is a relatively common health condition, when should we investigate hematuria and what should the evaluation consist of? How do we evaluate a patient’s risk for urinary tract malignancy? Dr. Aaron Potretzke, a urologist at Mayo Clinic joins us to discuss these questions.

Specific topics:

• Definition of hematuria
• Benign causes of hematuria
• Risk of malignancy in low, medium, and high-risk patients
• Stratifying malignancy risk in patients for genitourinary malignancy
• Recommended evaluation for patients with hematuria
• How to manage patients with persistent hematuria despite a negative evaluation
• Role of urine cytology in the evaluation of hematuria

Additional resources:

• American Urological Association hematuria guideline and algorithm: https://www.auanet.org/guidelines/guidelines/microhematuria

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.